Screener
Monte Rosa Therapeutics, Inc. GLUE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s debt-to-equity?
- Monte Rosa Therapeutics, Inc. (GLUE) reported debt-to-equity of 0.1× in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s debt-to-equity decreased by 49.2% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s debt-to-equity has grown at a 67.6% compound annual growth rate (CAGR), from 0× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Monte Rosa Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude